UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

WASHINGTON,D.C. 20549

FORM6-K

REPORTOF FOREIGN PRIVATE ISSUER

PURSUANTTO RULE 13a-16 OR 15d-16 UNDER

THESECURITIES EXCHANGE ACT OF 1934

Forthe month of August 2025

CommissionFile Number: 001-41115

GENENTASCIENCE S.P.A.

(Translationof registrant’s name into English)

ViaOlgettina No. 58

20132Milan, Italy

(Addressof Principal Executive Offices)

Indicateby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Indicateby check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicateby check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

OtherEvents

OnDecember 30, 2024, the Company and AGC Biologics S.p.A. (“AGC”) entered into the Second Amendment to the Development andMaster Services Agreement, effective as of March 6, 2019, and as amended as of March 5, 2024. In conjunction with entry into the SecondAmendment, the Company also entered into Work Statement No. 1 for AGC to manufacture, test, and release certain of the Company’scell therapy products and provide for a dedicated GMP suite. On August 1, 2025, the Company notified AGC of its intent to terminate WorkStatement No. 01, pursuant to Section 4.1 of the Second Amendment to the Development and Master Services Agreement, which would eliminatethe Company’s commitment to a dedicated suite effective August 1, 2026, but will allow AGC to continue to manufacture certain drugproducts for the Company in shared suites.

SIGNATURES

Pursuantto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf bythe undersigned hereunto duly authorized.

Dated:August 1, 2025